Chinese scientists have shown that early insulin therapy significantly benefits patients newly diagnosed with type 2 diabetes (T2D). This treatment reduces the risks of stroke and heart failure-related hospitalizations.
Led by Professor Weng Jianping of Anhui Medical University, a collaborative research group including experts from the University of Science and Technology of China, Southern Medical University, and Peking University studied 5,424 T2D patients over 24 years.
The results revealed that patients receiving early insulin therapy had a 31% lower risk of stroke and a 28% reduced risk of heart failure hospitalizations.
The study also noted improvements in biomarkers linked to cardiovascular risk, such as low-grade inflammation and endothelial function, among those treated early.
These findings, demonstrating the benefits of early insulin therapy, were published in the international journal Signal Transduction and Targeted Therapy in early June. They advocate its use as a primary treatment for newly diagnosed T2D patients.
